Search

Your search keyword '"Bruton, Rachel"' showing total 119 results

Search Constraints

Start Over You searched for: Author "Bruton, Rachel" Remove constraint Author: "Bruton, Rachel"
119 results on '"Bruton, Rachel"'

Search Results

1. Immunological imprinting of humoral immunity to SARS-CoV-2 in children

2. Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection

3. Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes

4. Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study

5. Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection

6. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

8. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia

9. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study

11. Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

13. Robust generation of neutralising antibodies against omicron variants following bivalent mRNA booster vaccine in elderly people aged >80 years

17. Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people

18. Immunological imprinting of humoral immunity to SARS-CoV-2 in children

19. COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia

20. mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273

21. Strong peak immunogenicity but rapid antibody waning following third vaccine dose in elderly residents of care homes

22. Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)

23. Additional file 2 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia

24. Additional file 3 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia

25. Additional file 1 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia

26. Additional file 4 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia

27. SARS-CoV-2 anti-spike antibody levels following second dose of ChAdOx1 nCov-19 or BNT162b2 in residents of long-term care facilities in England (VIVALDI)

29. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

30. mRNA COVID-19 vaccines induce enhanced antibody and cellular responses compared to ChAdOx1 or natural infection in children

31. mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant

32. Author response: mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant

33. Robust SARS-CoV-2-specific and heterologous immune responses after natural infection in elderly residents of Long-Term Care Facilities

35. Additional file 1 of Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people

36. Children develop robust and sustained cross-reactive spike-specific immune responses following SARS-CoV-2 infection

37. Booster Vaccination Strongly Enhances SARS-CoV-2-Specific Antibody and Cellular Responses in Elderly Residents of Care Homes

38. Reduced Antibody and Cellular Immune Responses Following Dual COVID-19 Vaccination Within Infection-Naïve Residents of Long-Term Care Facilities

39. Profile of Humoral and Cellular Immune Responses to Single BNT162b2 or ChAdOx1 Vaccine in Residents and Staff Within Residential Care Homes (VIVALDI Study)

40. Antibody Responses After First and Second COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukaemia

41. Impaired Neutralisation of SARS-CoV-2 Delta Variant in Vaccinated Patients With B Cell Chronic Lymphocytic Leukaemia

Catalog

Books, media, physical & digital resources